Sarepta Therapeutics, Inc. (NASDAQ:SRPT) reported Q2 2017 earnings this Afternoon, coming in at ($0.46) per share, beating Wall Street’s estimates of ($0.88) per Share. Revenue for the quarter came in at $35.01 million beating analyst estimates of $22.52 million
Analyst Coverage For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
These are 3 Hold Ratings, 16 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Buy (Score: 2.90) with a consensus target price of $61.00 , a potential (78.99% upside)Recent Insider Trading for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
- On 10/17/2016 Sandesh Mahatme, Insider, sold 30,000 with an average share price of $50.08 per share and the total transaction amounting to $1,502,400.00.
- On 9/22/2016 David T Howton, SVP, sold 7,000 with an average share price of $60.00 per share and the total transaction amounting to $420,000.00.
- On 9/22/2016 Edward M Md Kaye, CEO, sold 40,179 with an average share price of $60.00 per share and the total transaction amounting to $2,410,740.00.
- On 9/19/2016 David T Howton, SVP, sold 9,304 with an average share price of $50.00 per share and the total transaction amounting to $465,200.00.
- On 9/19/2016 Edward M Md Kaye, CEO, sold 24,352 with an average share price of $50.00 per share and the total transaction amounting to $1,217,600.00.
- On 9/19/2016 Jayant Aphale, VP, sold 35,000 with an average share price of $50.00 per share and the total transaction amounting to $1,750,000.00.
Recent Trading for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares of Sarepta Therapeutics, Inc. closed the previous trading session at 34.08 up +0.19 0.56% with 3,306,428 shares trading hands.